疱疹性眼病研究:局部皮质类固醇治疗单纯疱疹性基质角膜炎的对照试验
这项随机双盲安慰剂对照多中心试验纳入106例活动性单纯疱疹性基质角膜炎患者,比较局部泼尼松龙磷酸钠与安慰剂(均联合局部三氟胸苷)的疗效。结果显示皮质类固醇组治疗失败时间显著延长,持续或进展性基质角膜葡萄膜炎风险降低68%,基质角膜炎和葡萄膜炎消退时间显著缩短;6个月时两组视力结局和疱疹性眼病复发无显著差异。
要点
- 局部皮质类固醇可显著降低持续或进展性基质角膜葡萄膜炎风险达68%。
- 皮质类固醇组基质角膜炎和葡萄膜炎消退时间显著短于安慰剂组。
- 6个月时两组视力结局与疱疹性眼病复发无临床或统计学显著差异。
核心结论
- 本研究所用局部皮质类固醇方案在减少基质炎症持续或进展及缩短单纯疱疹性基质角膜炎病程方面显著优于安慰剂。
- 推迟使用皮质类固醇并观察数周会延迟基质角膜炎消退,但按6个月视力结局评估无有害影响。
研究设计与样本
- 随机、双盲、安慰剂对照、多中心临床试验。
- 纳入106例活动性单纯疱疹性基质角膜炎且入组前至少10天未接受任何皮质类固醇的患者。
- 患者分为安慰剂组(n=49)或皮质类固醇组(局部泼尼松龙磷酸钠;n=57),两组方案均在10周内逐渐减量。
- 两组均接受局部三氟胸苷治疗。
- 每周进行视力评估和裂隙灯生物显微镜检查持续10周,随后每两周一次再持续6周或直至退出试验,并在随机化后6个月复查。
主要发现
- 皮质类固醇组治疗失败时间(按特定标准定义为持续性或进展性基质角膜葡萄膜炎或不良事件)显著长于安慰剂组。
- 与安慰剂相比,皮质类固醇治疗使持续或进展性基质角膜葡萄膜炎风险降低68%。
- 即使两组均包含按最佳医学判断退出研究并接受局部皮质类固醇治疗的患者,皮质类固醇组从随机化到基质角膜炎和葡萄膜炎消退的时间仍显著短于安慰剂组。
- 随机化后6个月,皮质类固醇组与安慰剂组在视力结局或复发性疱疹性眼病方面未发现临床或统计学显著差异。
关键数值与推荐
- 治疗失败定义为持续性或进展性基质角膜葡萄膜炎或不良事件。
- 皮质类固醇治疗使持续或进展性基质角膜葡萄膜炎风险降低68%。
临床怎么用
- 对于活动性单纯疱疹性基质角膜炎且近期未使用皮质类固醇的患者,可考虑使用局部皮质类固醇联合局部抗病毒药物以缩短炎症病程。
- 推迟皮质类固醇并观察数周虽会延迟消退,但6个月视力结局无损害,可在密切监测下个体化决策。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: To evaluate the efficacy of topical corticosteroids in treating herpes simplex stromal keratitis. METHODS: The authors performed a randomized, double-masked, placebo-con- trolled, multicenter clinical trial of 106 patients with active herpes simplex stromal keratitis who had not received any corticosteroids for at least 10 days before study enrollment. Patients were assigned to the placebo group (n = 49) or the steroid group (topical prednisolone phosphate; n = 57); both regimens were tapered over 10 weeks. Both groups received topical trifluridine. Visual acuity assessment and slit-lamp biomicroscopy were performed weekly for 10 weeks, every other week for an additional 6 weeks or until removal from the trial, and at 6 months after randomization. RESULTS: The time to treatment failure (defined by specific criteria as persistent or progressive stromal keratouveitis or an adverse event) was significantly longer in the steroid group compared with the placebo group. Compared with placebo, corticosteroid therapy reduced the risk of persistent or progressive stromal keratouveitis by 68%. The time from randomization to resolution of stromal keratitis and uveitis was significantly shorter in the steroid group compared with the placebo group even though both groups included patients who were removed from the study and treated with topical corticosteroids according to best medical judgment. Nineteen (33%) of the steroid-treated patients and 11 (22%) of the placebo-treated patients completed the 10 weeks of protocol therapy and had stable, noninflamed corneas after 16 weeks. At 6 months after randomization, no clinically or statistically significant differences in visual outcome or recurrent herpetic eye disease were identified between the steroid and placebo groups. CONCLUSIONS: The topical corticosteroid regimen used in this study was significantly better than placebo in reducing persistence or progression of stromal inflammation and in shortening the duration of herpes simplex stromal keratitis. Postponing steroids during careful observation for a few weeks delayed resolution of stromal keratitis but had no detrimental effect as assessed by visual outcome at 6 months.
引用
- Wilhelmus KR, Gee L, Hauck WW, et al. Herpetic Eye Disease Study: A Controlled Trial of Topical Corticosteroids for Herpes Simplex Stromal Keratitis. Ophthalmology. 2020. PMID: 32200827. doi:10.1016/j.ophtha.2020.01.037
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。